(12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 20090246185A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida et al. (43) Pub. Date: Oct. 1, 2009 (54) CARDIAC DYSFUNCTION-AMELIORATING (30) Foreign Application Priority Data AGENT OR CARDAC FUNCTION-MANTAININGAGENT Mar. 13, 2006 (JP) ................................. 2006-066992 Nov. 21, 2006 (JP) ................................. 2006-314034 (75) Inventors: Hideyuki Kishida, Hyogo (JP); O O Kenji Fujii, Hyogo (JP); Hiroshi Publication Classification Kubo, Hyogo (JP); Kazunori (51) Int. Cl. Hosoe, Hyogo (JP) A6II 3L/22 (2006.01) CD7C 43/23 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) SUGHRUE MION, PLLC (52) U.S. Cl. ........................................ 424/94.1:568/651 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (57) ABSTRACT WASHINGTON, DC 20037 (US) An object of the present invention is to provide a highly safe oral composition Superior in a cardiac dysfunction-amelio (73) Assignee: KANEKA CORPORATION, rating or cardiac function-maintaining action. The present OSAKA-SHI, OSAKA (JP) inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of (21) Appl. No.: 12/282,448 particularly, reduced coenzyme Q10 from among highly safe coenzyme Q affords a composition useful for amelioration of (22) PCT Filed: Mar. 9, 2007 cardiac dysfunction and maintenance of cardiac function. Accordingly, the present invention provides a cardiac dys (86). PCT No.: PCT/UP2007/O54.643 function-ameliorating agent or cardiac function-maintaining agent containing reduced coenzyme Qas an active ingredient, S371 (c)(1), and a pharmaceutical product, a food, an animal drug, a feed (2), (4) Date: Dec. 23, 2008 and the like, which contain the agent. US 2009/0246.185 A1 Oct. 1, 2009 CARDAC DYSFUNCTION-AMELORATING orporeal energy source. In human, coenzyme Q10 in which AGENT OR CARDAC the side chain of coenzyme Q has 10 repeat structures is the FUNCTION-MANTAININGAGENT main component, and aids the life activity of cells and tissues. In Japan, oxidized coenzyme Q10 is used as a drug for con TECHNICAL FIELD gestive heart failure, and in Europe and the United States, 0001. The present invention relates to a cardiac dysfunc oxidized coenzyme Q10 is widely used as a health food. tion-ameliorating agent or cardiac function-maintaining There are reports on the effectiveness for cardiac diseases agent comprising reduced coenzyme Q as an active ingredi other than cardiac failure. Such as angina pectoris (non-patent ent. reference 1), myocardial infarction (non-patent reference 2) and the like, as well as hypertension (non-patent reference 3). BACKGROUND ART 0006 An important characteristic of coenzyme Q10 is its high Safety. It has been reported that consecutive administra 0002 Cardiac disease is one of the important causes of death for Japanese people, of which angina pectoris, myocar tion of 1200 mg/kg/day for 52 weeks in a chronic toxicity test dial infarction and cardiac failure are highly important as the of oxidized coenzyme Q10 in rats did not show a toxic influ pathology potentially directly causing death. "Easily-fa ence (non-patent reference 4). For human (body weight 50 tigued, “short breath”, “episode of chest pain”, “palpita kg), 1200 mg/kg/day corresponds to 60 g/day. In view of the tion”, “dizziness, faint” and the like are symptoms frequently fact that the usual dosage of oxidized coenzyme Q10 used as associated with cardiac diseases. For example, "episode of a health food in Europe and the United States is 100-300 chest pain' is a symptom mostly related to angina pectoris mg/day, coenzyme Q10 is an extremely highly safe Supple myocardial infarction, and “easily-fatigued, “short breath’ ment material. and "palpitation' are symptoms mostly related to cardiac 0007. It is known that generally about 40-90% of coen failure. Angina pectoris is a state in which arteriosclerosis is Zyme Q in the living organisms is in a reduced form. It has formed in the coronary of the heart, the arteriosclerosis causes also been reported that a pharmaceutical composition con stenosis which prevents sufficient supply of blood to the taining reduced coenzyme Q is Superior in oral absorbability cardiac muscle, and the cardiac muscle runs short of oxygen (patent reference 3). However, reduced coenzyme Q is diffi and produces a chest pain. Myocardial infarction refers to the cult to handle since it is easily oxidized by oxygen in the air, pathology where the coronary is completely obstructed and and the oxidized coenzyme Q is generally conventionally blood supply is completely prevented, thus causing a partial commercially available and is used as a pharmaceutical agent death of the heart. Cardiac failure refers to the pathology where the hematological Supply is insufficient for the sys orfood because once ingested, oxidized coenzyme Q is con temic demand, since the pumping function of the heart verted to reduced coenzyme Q in the body. As mentioned became lower. Cardiac failure is the pathology that com above, the action of oxidized coenzyme Q on the cardiac monly occurs at late stages of any cardiac diseases, which function has already been confirmed and oxidized coenzyme shows characteristic symptoms of short breath, generalized Q has been put to practical use. Due to the aforementioned fatigability, palpitation, Swelling of lower leg and the like. circumstances, however, application of reduced coenzyme Q 0003 Angina pectoris, myocardial infarction and cardiac itself to a cardiac function associated disease has not been failure are treated by a drug therapy, a catheter treatment, a tried. For example, there are reports on the methods for the Surgical treatment and the like. Particularly, in cardiac dis treatment and/or prophylaxis of blood vessel diseases char eases, a drug therapy is highly important among the treat acterized by a shortage of nitric oxide (NO), comprising ments. Therefore, many drugs are currently used for the treat combining a therapeutic agent for angina pectoris and an ment of cardiac diseases. Nevertheless, cardiac disease is the antioxidant, which include a case reciting oxidized coenzyme second major cause of death next to cancer for Japanese Q and reduced coenzyme Q as simple examples of the anti people, and the number thereof keeps rising due to the west oxidant (patent reference 4), and a report on a composition ernized eating habits and lifestyle. In the circumstances, there that enhances cell energy metabolism by combining oxidized is a demand for the development of a pharmaceutical product coenzyme Q10 or reduced coenzyme Q10 with two or more or functional food showing an ameliorating or prophylactic kinds of cytochromes a, b, c and the like (patent reference 5). action on cardiac dysfunction, which is safe and can be con Nevertheless, the action of reduced coenzyme Q itself on the tinuously ingested every day. cardiac function has not been confirmed. 0004 Such reports relating to a composition having a car diac dysfunction-ameliorating or cardiac function-maintain 0008 patent reference 1: JP-A-2005-132758 ing action concern a composition or food and drink contain 0009 patent reference 2: JP-A-2005-239581 ing, as an active ingredient, arachidonic acid or a compound (0010 patent reference 3: JP-A-10-109933 containing arachidonic acid as a constituent fatty acid (patent 00.11 patent reference 4: National Publication of Interna reference 1), a composition containing pycnogenol (patent tional Patent Application No. 2003-5 14020 reference 2) and the like. 0005 Coenzyme Q is an essential component widely dis 0012 patent reference 5: National Publication of Interna tributed in living organisms from bacterium to mammal, and tional Patent Application No. 2004-518712 is known to be an electron transport system constituent com (0013 non-patent reference 1: Am J Cardiol 1985; 56(4): ponent of mitochondria in the cells of a living body. Coen 247-51. Zyme Q functions as a transport component in the electron (0014) non-patent reference 2: Mol Cell Biochem 2003: transport system by repeating oxidization and reduction in 246(1-2): 75-82. mitochondria, and is one of the coenzymes necessary for 0015 non-patent reference 3: Biofactors 2003; 18(1-4): producing ATP (adenosine triphosphate), which is an intrac 91-100. US 2009/0246.185 A1 Oct. 1, 2009 0016 non-patent reference 4: J Agric Food Chem 1999; 0029 11 A method of controlling cardiac function, com 47: 3756-3763. prising administering a cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent comprising a DISCLOSURE OF THE INVENTION reduced coenzyme Q represented by the following formula Problems to be Solved by the Invention (1): 0017. An object of the present invention is to provide a highly safe composition Superior in a cardiac dysfunction (1) ameliorating or cardiac function-maintaining action. OH Means of Solving the Problems H3CO CH3 0018. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of particularly, reduced coenzyme Q10 from among highly safe coenzyme Q is effective for the OH amelioration of cardiac dysfunction and maintenance of car diac function. Accordingly, the present invention is as fol wherein n is an integer of 1-12, as an active ingredient, to a lows. Subject of administration. 0019 1A cardiac dysfunction-ameliorating agent or car 0030 12. The method of 11, wherein the aforemen diac function-maintaining agent comprising reduced coen tioned Subject of administration is a healthy human or healthy Zyme Q represented by the following formula (1): animal having a potential risk of cardiac dysfunction. 0031. 13. The method of 11, wherein the aforemen (1) tioned subject of administration is suffering from cardiac OH dysfunction and under a treatment thereof, and the method further comprises administering the aforementioned cardiac H3CO CH3 dysfunction-ameliorating agent or cardiac function-main taining agent as an aid of the treatment.